Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults
January 30, 2024 11:39 ET
|
Defender Pharmaceuticals, Inc.
ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S....
Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386’s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
October 24, 2023 08:00 ET
|
Defender Pharmaceuticals, Inc.
First study evaluates DPI-386 alone and in combination with sensory augmentation to effectively mitigate motion sickness and improve task performance, in comparison to placebo. Second study evaluates...
FDA Accepts Defender Pharmaceuticals’ New Drug Application for Intranasal Scopolamine Gel
September 26, 2023 08:00 ET
|
Defender Pharmaceuticals, Inc.
PDUFA date of January 26th, 2024 Assigned Priority Review Status at the Request of the US NavySubmission based on five Phase III clinical trials, including overwhelmingly positive results from the -33...
Defender Pharmaceuticals Phase 3 Motion Sickness Trial Results Selected for Presentation at 2023 Military Health System Research Symposium (MHSRS)
August 10, 2023 11:32 ET
|
Defender Pharmaceuticals, Inc.
Subjects receiving DPI-386 (intranasal scopolamine gel) demonstrated significantly lower incidence of nausea, vomiting or the need for rescue medication in comparison to individuals administered...
Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Products to Treat Tropical Diseases
July 31, 2023 15:12 ET
|
Defender Pharmaceuticals, Inc.
ST. LOUIS, July 31, 2023 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that it had...
Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for Prevention of Nausea and Vomiting Induced by Motion in Adults
July 26, 2023 11:18 ET
|
Defender Pharmaceuticals, Inc.
Submission based on five Phase III clinical trials, including overwhelmingly positive results from the -33 Phase 3 studyAn estimated one in three adults will suffer motion sickness at some point1 ST....
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
June 05, 2023 09:47 ET
|
Defender Pharmaceuticals, Inc.
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced positive results...